BRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B – Reuters
|
BRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B
Reuters … * Uniqure NV – expects to recognize in Q3 of 2017 remaining deferred revenue of about $14 million from non-refundable payments received from Chiesi in 2013. * Uniqure says does not expect transaction will impact its previous cash guidance … |
